NDA 021258 · Bayer Hlthcare
Climara Pro
Estradiol, Levonorgestrel · Transdermal · Estrogen; Progestin; Progestin-containing Intrauterine System
Last checked: Nov 20, 2026Latest source record: Feb 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Nov 21, 2003
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,701
351 Phase 3, 176 recruiting
FAERS reports
2,062
253 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, BREAST CANCER, and ENDOMETRIAL CANCER Estrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia The Women's Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo [see Warnings and Precautions (5.1) , and Clinical Studies (14.5) ]. The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age and older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5...
What it is approved for
From the label in effect Mar 26, 2026.
Climara Pro is indicated for: Climara Pro is an estrogen plus progestin indicated in a woman with a uterus for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) Prevention of Postmenopausal Osteoporosis ( 1.2 ) Limitations of Use: When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis. 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Prevention of Postmenopausal Osteoporosis Limitation of Use When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis.
Mechanism: Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After...
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- CLIMARA PRO · ESTRADIOL 0.045MG/24HR; LEVONORGESTREL 0.015MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Estradiol" as an intervention, any sponsor and status, largest first.
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyPivotal-lookingActive, not recruiting
Medical Research CouncilGovernment (non-federal)
NCT00268476 · 11,992 participants · Start Jul 8, 2005 · Primary completion Mar 2026
Drug: Celecoxib; Docetaxel and 7 more · For: Prostate Cancer
Sites: Lausanne, Switzerland; Winterthur, Switzerland; Chur, Switzerland · 120 sites in all
- Short-term Effects of Transdermal Estradiol on Female COVID-19 PatientsPivotal-lookingCompleted
Istanbul University - CerrahpasaAcademic, hospital or other
NCT05774405 · 9,169 participants · Start Jul 1, 2020 · Primary completion Jul 31, 2021
Drug: Climara 0.1Mg/24Hr Transdermal System · For: COVID-19; Hormone Replacement Therapy
Sites: Istanbul, Turkey (Türkiye)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00006324 · 6,360 participants · Start Dec 1999
Drug: Ethinyl estradiol/levonorgestrel; Medroxyprogesterone acetate · For: HIV Infections
Sites: Research Triangle Park, North Carolina
- A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Women's HealthTeva (TEVA)
NCT00996580 · 3,597 participants · Start Oct 2009 · Primary completion Sep 2011
Drug: DR-103 · For: Pregnancy Prevention
Sites: Montgomery, Alabama; Phoenix, Arizona; Tucson, Arizona · 94 sites in all
- Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)Pivotal-lookingTerminated
Organon and CoIndustry
NCT01656434 · 3,173 participants · Start Nov 2, 2012 · Primary completion Feb 12, 2014
Drug: NOMAC-E2; NETA-EE and 2 more · For: Contraception
- Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral ContraceptivePivotal-lookingTerminated
Organon and CoIndustry
NCT05264506 · 3,055 participants · Start Feb 17, 2022 · Primary completion Jan 12, 2024
Drug: NOMAC-E2 COC · For: Contraception
Sites: Birmingham, Alabama; Dothan, Alabama; Mobile, Alabama · 103 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
- A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT01178125 · 2,858 participants · Start Aug 2010 · Primary completion Jan 2013
Drug: DR-102 · For: Contraception; Female Contraception
Sites: Montgomery, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 62 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product adhesion issue668
- product physical issue348
- device adhesion issue268
- wrong technique in product usage process265
- hot flush230
- application site rash194
- drug ineffective157
- product quality issue139
- application site pruritus110
- application site erythema102
- application site irritation94
- device breakage94
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 13 |
| 2008 | 104 |
| 2009 | 106 |
| 2010 | 110 |
| 2011 | 82 |
| 2012 | 105 |
| 2013 | 67 |
| 2014 | 88 |
| 2015 | 97 |
| 2016 | 118 |
| 2017 | 239 |
| 2018 | 159 |
| 2019 | 101 |
| 2020 | 95 |
| 2021 | 89 |
| 2022 | 71 |
| 2023 | 90 |
| 2024 | 96 |
| 2025 | 124 |
| 2026 | 101 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Climara Pro (Estradiol/Levonorgestrel)
2024 spending
$3.7M
Beneficiaries
2,248
8,334 claims
Per beneficiary
$1,633
$61.16 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,255,418 |
| 2021 | $3,361,509 |
| 2022 | $3,539,843 |
| 2023 | $3,615,168 |
| 2024 | $3,671,214 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of Soy Isoflavones on Measures of Estrogenicity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Viscardi G, Back S, Ahmed A, et al. · Adv Nutr 2025 · Systematic Review, Meta-Analysis
- Systematic Review and Meta-analysis: Changes of Gut Microbiota before and after Menopause.
Yang M, Wen S, Zhang J, et al. · Dis Markers 2022 · Meta-Analysis, Systematic Review
- Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis.
Comini ACM, Carvalho BM, Moreira MJB, et al. · Clin Breast Cancer 2023 · Meta-Analysis, Systematic Review
- Association Between Estradiol and Human Aggression: A Systematic Review and Meta-Analysis.
Wang Y, Wang H, Cai J, et al. · Psychosom Med 2023 · Meta-Analysis, Systematic Review
- Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol.
Hodis HN, Mack WJ, Henderson VW, et al. · N Engl J Med 2016 · Comparative Study, Randomized Controlled Trial
- The Effect of Sex Hormones on Joint Ligament Properties: A Systematic Review and Meta-analysis.
Gilmer G, Crasta N, Tanaka MJ · Am J Sports Med 2025 · Systematic Review, Meta-Analysis
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.